Replies to post #172308 on Avid Bioservices Inc (CDMO)

[biopharm]

Peregrine Pharmaceuticals : KOL : Dmitry Gabrilovich

Dendritic Cells Transfected with Adenoviral Vectors as vacciness

Author(s): Joseph Senesac, Dmitry Gabrilovich, Samuel Pirruccello, James E. Talmadge

Pub. Date: Jun-02-2014; DOI: 10.1007/978-1-4939-0345-0_10; Page Range: 97-118

-----------------------------------------------------------

10. Dendritic Cells Transfected with Adenoviral Vectors as vacciness
By: Joseph Senesac 1, Dmitry Gabrilovich 2, Samuel Pirruccello 3, James E. Talmadge 3 Contact Information
Abstract
Full Text | Download PDF (666K)

[Email] | [Printer Friendly] | [Add To My Protocols] | [Tag it]
Dendritic cells (DCs) are critical to the initiation of a T-cell response. They constitute the most potent antigen-presenting cell (APC) endowed with the unique capacity to stimulate an antigen-specific T-cell responses by naïve T cells. Adenoviruses (Ad) have high transduction efficiency for many cell types including cells of hematopoietic origin independent of their mitotic status, and replication-defective Ad have demonstrated a safety profile clinically. Further, Ad vectors provide a high level of transgene expression, and Ad-transduced DCs can effectively present antigenic proteins. In this chapter, we outline a functionally closed, good manufacturing protocol for the differentiation of monocytes into DCs and transduction by Ad vectors. Basic functional and phenotypic release assays are provided, as well as contrasting research approaches for Ad-transduced DC-based vacciness.

Affiliation(s): (1) Bellicum Pharmaceuticals, Houston, TX, USA
(2) H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
(3) University of Nebraska Medical Center, Omaha, NE, USA
Book Title: Cancer vacciness : Methods and Protocols
Series: Methods in Molecular Biology | Volume: 1139 | Pub. Date: Jun-02-2014 | Page Range: 97-118 | DOI: 10.1007/978-1-4939-0345-0_10


http://www.springerprotocols.com/BookToc/doi/10.1007/978-1-4939-0345-0

------------------------------------------------------

[biopharm]

Peregrine KOL : Dmitry Gabrilovich :

Reciprocal Relationship between Myeloid-Derived Suppressor Cells and T Cells

J Immunol 2013 191:17-23;

http://www.jimmunol.org/content/191/1/17.full.pdf+html

--------------------------------------------------

... just another example of how a Peregrine KOL does not need to actually even mention Peregrine or Bavituximab --- but only needs to provide medical expertise to what happens within Notch Signaling and the relationships between MDSC's / T-cells...etc..etc and how it provides the "optimal immune response".

... because those relationships are directly related to the MOA of Bavituximab and the effects of PS Targeting.. ... so in fact, its just like years ago when a group of people tried to tell about the world is round and you will not fall off the edge of the earth : ) ... before you know it, people are traveling the globe, just like many PS Targeting agents will be traveling to millions of these stressed/infected/cancerous cells among Billions of people globally.